Capturing Patients’ Experience in Their Daily Lives

One of the challenges with rare diseases is how different their effects can be from one person to another. In order to get a deeper understanding of the impact and variation of the rare autoimmune condition myasthenia gravis on people, Argenx launched MyRealWorld MG, an app-based study that’s collecting real-world, longitudinal data from 2,000 patients over two years. We spoke to Deb Gelinas, neuromuscular executive director at Argenx, about myasthenia gravis, the company’s MyRealWorld MG study, and how she hopes the data will provide new insights into the rare, autoimmune condition.